key: cord-0686113-vb25u7mc
authors: Kovalic, Alexander J.; Huang, Glen; Thuluvath, Paul J.; Satapathy, Sanjaya K.
title: Elevated Liver Biochemistries in Hospitalized Chinese Patients with Severe COVID‐19: Systematic Review and Meta‐analysis
date: 2020-07-21
journal: Hepatology
DOI: 10.1002/hep.31472
sha: d98e8dfa59bcfb5cc8fbda49814037154adb89e5
doc_id: 686113
cord_uid: vb25u7mc

BACKGROUND & AIMS: Several recent studies have reported an abnormal liver chemistry profile among patients with coronavirus disease 2019 (COVID‐19), although its clinical significance remains unknown. APPROACH & RESULTS: This novel systematic review and meta‐analysis identified six studies of 586 patients delineating liver chemistries among patients with severe/critical illness versus mild cases of COVID‐19 infection. Patients with severe/critical illness with COVID‐19 infection have increased prevalence of coronary artery disease (CAD), cerebrovascular disease, and chronic obstructive pulmonary disease (COPD) as compared to mild cases. A significant association between severe/critical COVID‐19 infections with elevations in aspartate aminotransferase (AST) (pooled mean difference [MD], 11.70 U/L; 95% confidence interval [CI], 2.97, 20.43; P = 0.009), elevated total bilirubin (pooled MD, 0.14 mg/dL; 95% CI, 0.06, 0.22; P = 0.0005), and decreased albumin (pooled MD, –0.68 g/L; 95% CI, –0.81, –0.55; P < 0.00001) was noted. There was also a trend toward elevated alanine aminotransferase (ALT) levels among these severe cases (pooled MD, 8.84 U/L; 95% CI, –2.28, 19.97; P = 0.12); however, this did not reach statistical significance. More severe/critically ill cases were associated with leukocytosis, neutrophilia, lymphopenia, elevated creatinine kinase, elevated lactate dehydrogenase (LDH), and elevated prothrombin time (PT). CONCLUSIONS: Comorbidities, including CAD, cerebrovascular disease, and COPD, are more prevalent in hospitalized Chinese patients with severe/critical illness from COVID‐19, and these patients are more likely to manifest with abnormal liver chemistries. Further prospective studies are crucial to understand the pathophysiologic mechanisms underlying the hepatic manifestations of the novel COVID‐19 infection and its clinical significance.

The primary outcomes for this meta-analysis were as follows: (1) liver chemistries (AST, ALT, total bilirubin, albumin); (2) demographic data (age, gender, comorbidities); (3) laboratory parameters from complete blood count (CBC), comprehensive metabolic panel (CMP), or coagulation testing (white blood count [WBC] , neutrophils, lymphocytes, platelets, creatinine, creatinine kinase, lactate dehydrogenase [LDH], prothrombin time [PT] , activated partial thromboplastin time [aPTT] ); (4) mortality.

The authors extracted data from the literature search, and any disagreements were resolved by consensus. Ambiguity in the reported data was attempted to be resolved by e-mailing the corresponding author of the study where appropriate. Author names, dates, study type, setting of study, number and characteristics of patients, and treatment outcomes were gathered for all included studies.

Nonrandomized studies were assessed by the Newcastle-Ottawa Scale (NOS). (5) The authors determined the quality of selection, comparability, and exposure/outcome in the NOS. Each form of bias was awarded either a low, high, or unclear risk of bias. A funnel plot was calculated to determine the presence of publication bias.

This meta-analysis was performed using Review Manager (RevMan, version 5.3, The Cochrane Collaboration, Denmark). Odds ratios (ORs) were used as a summary measure of efficacy for dichotomous data, and mean differences (MDs) were used between groups for continuous variables; 95% confidence intervals (CIs) were reported for both measures. If medians and interquartile ranges (IQRs) were provided in the included studies instead of MDs and standard deviations, the MD and standard deviations were imputed as described in other studies (6) (7) 8) as well as the Cochrane

Handbook for Systematic Reviews of Interventions. (9) Data were considered statistically insignificant if P > 0.05, OR includes 1.00, or MD includes 0. Statistical heterogeneity was assessed using the I 2 statistic. I 2 values of 0% to 25%, 25% to 50%, 50% to 75%, and more than 75% were awarded values of homogeneity, mild heterogeneity, moderate heterogeneity, and high heterogeneity, respectively. If significant heterogeneity was present (I 2 50%), the random effects model was used to pool the  effect sizes of included studies and subgroup analyses; if no significant heterogeneity was found (I 2 < 50%), the fixed-effect model was used. (10, 11) Publication bias was determined by Egger's regression asymmetry test. (12) Funnel plots were qualitatively assessed by visual inspection based on logarithmic ORs plotted versus their standard errors. (13) Asymmetric funnel plots represented studies with high risk of publication bias.

The data search, literature review, and study selection are outlined in Fig. 1 . Overall, 455 clinical studies were identified based on the predefined inclusion and exclusion criteria. Studies that did not have an appropriate clinical comparison between groups or present enough data to perform a quantitative meta-analysis were excluded. In the end, six studies with 586 patients were finalized that satisfied all of these criteria. (14) (15) (16) (17) (18) (19) Also of note, all of these studies present data from COVID-19 positive patients from China. Five are from Wuhan and the province of Hubei. The final study details a patient cohort from the neighboring province of Chongqing. (16) All data were included from hospitalized patients with laboratory data collected and analyzed upon presentation. Quality assessment of the included studies is provided in Supporting Table S1 . 

Funnel plots were generated for the outcomes of this meta-analysis and are demonstrated in Supporting Figs. S3-S7. Where appropriate, 95% CIs were included for fixed-effect model analysis.

Overall, there was no asymmetry noted in the funnel plots to suggest a large degree of publication bias.

As the current pandemic continues to sweep the globe, there will inevitably be an increasing amount of clinical data from Europe and North American regarding liver injury among patients with COVID-19, however at the time of this meta-analysis, the data have come exclusively from China. There remains a paucity of data on liver histopathology and limited autopsy case reports reveal microvesicular steatosis in addition to lobular and portal inflammation, although not as exaggerated as inflammation seen in the lungs. (20) Our study shows that abnormalities of liver chemistries are more common in severe COVID-19 disease and more likely to be seen in those with other serious

This article is protected by copyright. All rights reserved comorbidities. Based upon circumstantial evidence, the CDC and the AASLD Expert Panel has suggested that there will be a heightened health care burden among patients with chronic liver diseases, especially those requiring liver transplantation. (21, 22) Our study appears to support the above statement since patients with NASH cirrhosis or those waiting liver transplant are likely to have significant comborbidities.

Several studies from Europe and North America have emerged recently. ( (25, 26) One the other hand, a large propensity-matched study has reported that patients with chronic liver disease and COVID-19 have a three-fold higher mortality risk as compared to patients without liver disease. (27) Conversely, two other meta-analyses have recently failed to demonstrate a link between chronic liver disease and either mortality or severity of COVID-19 infection. (28, 29) Mechanism of liver injury and its relationship with severity of COVID-19 infection is largely speculative. Similar to previous SARS-CoV infections, the binding and uptake by the angiotensinconverting enzyme 2 (ACE2) cholangiocyte receptor has been demonstrated to mediate liver damage among patients with COVID-19. (30) Not only does the degree of AST or ALT elevation appear to correlate with the severity of COVID-19 infection, but this mechanism for liver injury appears to be mediated by an up-regulation of ACE2 also among hepatocytes in a mouse model. (31) Other etiologies for liver injury include underlying liver disease, medications including experimental drugs, and in severe cases, the cytokine storm (through tumor necrosis factor α (TNF-), interleukin [IL]-6, or IL-18) as well as the ischemic hypoxia-reperfusion that accompanies more severe COVID-19

infections. (32) 

This article is protected by copyright. All rights reserved Furthermore, characterization of baseline "chronic liver disease" remains ill-defined among these studies and warrants further investigation. Many of these laboratory findings, such as aberrancies in liver chemistries, low platelet count, decreased albumin, or prolonged PT, could be explained by an acute COVID-19 infection but also may be influenced by underlying cirrhosis or viral hepatitis that is not clearly reported among these included studies.

The characterization of liver injury among COVID-19 infection remains paramount with respect to potential therapeutic options. Hydroxychloroquine (HCG) has been used in many countries as a potential therapeutic option against COVID-19, (33) and although hepatotoxicity is relatively uncommon, this drug is metabolized by the liver and has been reported to cause acute liver injury in select cases. (34) Furthermore, the use of antiviral therapies has undergone increased investigation.

Remdesivir, a novel antiviral agent that acts as an RNA-chain terminator, has been demonstrated to be effective in vitro, and in early clinical trials in the US. (35) Recent published studies on remdesvir have shown infrequent liver test abnormalities among other side effects. (36) (37) (38) However, elevation of

This article is protected by copyright. All rights reserved AST or ALT greater than five times the upper limit of normal remains an exclusion criterion for initiation of remdesivir among COVID-19 patients, and this may exclude many patients with preexisting liver disease from receiving remdesvir. The true incidence of remdesvir hepatotoxicity is an area for further research. Preliminary studies of IL-6 inhibitor, tocilizumab in patients with COVID-19 also suggest that this drug also may be associated with uncommon hepatotoxicity. (39) Among preliminary data from a study reporting the first hospitalized cases of COVID-19 in the United States, all patients treated with remdesivir developed transaminitis during their clinical course. (40) As demonstrated in this systematic review and meta-analysis, the patients suffering from more severe or critical COVID-19 infections have significantly increased liver chemistries. This clinical finding poses quite a dilemma for future patients infected with COVID-19 because many of the current investigational or ongoing randomized controlled trials are excluding patients with values of AST or ALT greater than five times the upper limit of normal. (41) (42) (43) Therefore, further characterization and recognition of liver injury is vital among patients harboring severe/critical COVID-19 infections, particularly if one of the few therapeutic options is predicated on the status of underlying liver chemistries.

As the COVID-19 pandemic continues to afflict more individuals across the globe, both the incidence and clinical significance of liver injury among this patient population will be important to analyze. In this novel systematic review and meta-analysis, the characterization of severe or critically ill patients as compared to individuals suffering from mild cases of COVID-19 is described in detail. There appears to be a significant correlation of aberrant liver chemistries, in addition to CAD, cerebrovascular disease, COPD, leukocytosis, neutrophilia, lymphopenia, elevated creatinine kinase, elevated LDH, and increased PT, among patients with severe or critical illness from COVID-19 as Studies that did not include enough raw data to perform quantitative meta-analysis

This article is protected by copyright. All rights reserved 

World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

Liver injury in COVID-19: management and challenges

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group

The Newcastle-Ottawa Scale [NOS] for assessing the quality of nonrandomised studies in meta-analyses

Estimating the mean and variance from the median, range, and the size of a sample

Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration

Meta-Analysis and Subgroups

Interpretation of subgroup analyses in systematic reviews: A tutorial

Accepted Article This article is protected by copyright. All rights reserved 12

Bias in meta-analysis detected by a simple, graphical test

Publication bias in clinical research

Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study

Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing

Clinical Characteristics of 138 Hospitalized Patients With

Novel Coronavirus-Infected Pneumonia in Wuhan, China

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement

What to Know About Liver Disease and COVID-19

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Accepted Article This article is protected by copyright. All rights reserved 24

Baseline Characteristics and Outcomes of 1591

Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

Implications of COVID-19 for patients with pre-existing digestive diseases

Clinical Characteristics and Outcomes of COVID-19 Among Patients with Pre-Existing Liver Disease in United States: A Multi-Center Research Network Study

Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis

Chronic liver disease is not associated with severity or mortality in Coronavirus disease 2019 (COVID-19): a pooled analysis

Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection

Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

All rights reserved 34

COVID-19 Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia

First 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Identifier NCT04292899. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease

National Library of Medicine (US)

Compared to Standard of Care Treatment [accessed

Bethesda (MD): National Library of Medicine (US)

We thank Alexander Kovalic for substantial contributions to conception and design of the study, acquisition of data/analysis and interpretation of data, and drafting, critical revisions, and final approval of the article; Glen Huang for substantial contributions to acquisition of data/analysis and interpretation of data and drafting, critical revisions, and final approval of the article; Muhammad Ali Khan and Fuad Zain for contributions with the finalization of figures and tables; and Paul Thuluvath and Sanjaya Satapathy for substantial contributions to conception and design of the study, interpretation of data, and critical revisions and final approval of the article.

This article is protected by copyright. All rights reserved Heterogeneity: Chi 2 = 4.14, df = 4 (P = 0.39); I 2 = 3% Test for overall effect: Z = 3.48 (P = 0.0005) Heterogeneity: Chi 2 = 1.96, df = 2 (P = 0.38); I 2 = 0% Test for overall effect: Z = 10.06 (P = 0.00001)